ArticleMMWR. Morbidity and mortality weekly report2022
Reduced Risk for Mpox After Receipt of 1 or 2 Doses of JYNNEOS Vaccine Compared with Risk Among Unvaccinated Persons - 43 U.S. Jurisdictions, July 31-October 1, 2022.
Article in MMWR. Morbidity and mortality weekly report, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 2 syntheses or guidelines pooled it, 113 citations in OpenAlex.
- Predicting vaccine effectiveness for mpox.Nature communications · 2024Pooled it
- Clinical Features, Antiviral Treatment, and Patient Outcomes: A Systematic Review and Comparative Analysis of the Previous and the 2022 Mpox Outbreaks.The Journal of infectious diseases · 2023Pooled it
- Trial
- Equivalence of freeze-dried and liquid-frozen formulations of MVA-BN as smallpox and mpox vaccine.Human vaccines & immunotherapeutics · 2024Trial
- Mpox Outbreaks Beyond Historically Endemic Regions: A Clinical Review of Vaccination Strategies and Public Health Challenges.Dermatology (Basel, Switzerland) · 2026Review
- Assessing the impact of vaccination and behavioural change on Mpox transmission in high-risk groups in the Democratic Republic of Congo using an age-structured mathematical model.One health (Amsterdam, Netherlands) · 2026Article
- Article
- Pre-exposure vaccination in the high-risk population is crucial in controlling mpox resurgence in Canada.BMC infectious diseases · 2025Article
- Optimal deployment of limited vaccine supplies to control mpox outbreaks.NPJ vaccines · 2025Article
- From Yesterday to Tomorrow: How Vaccine Platforms Have Shaped the Vaccine and Treatment Evaluation Units.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
- Mpox containment strategies in China, 2022-2023: from preparedness to legal management.BMJ global health · 2025Review
- Exploring monkeypox virus antibody levels: insights from human immunological research.Virology journal · 2025Review
- Monkeypox Virus: WHO's Second Public Health Emergency of International Concern Within 2 Years.Microbial biotechnology · 2025Review
- Assessing Attitudes and Knowledge of Mpox Vaccine Among Unvaccinated Men Who Have Sex With Men.Sexually transmitted diseases · 2025Article
- Combining mpox vaccination and behavioural changes to control possible future mpox resurgence among men who have sex with men: a mathematical modelling study.BMJ public health · 2025Article
- Genomic variability and immunological aspects involved in response to MPXV infection.Frontiers in pharmacology · 2025Review
- A retrospective chart review and thematic analysis of patients seeking mpox vaccination during the initial outbreak in 2022-2023: evaluation of access, motivations, and stigma.BMC public health · 2024Article
- Prospective observational study on scar sequelae after MPOX infection: an analysis of 40 patients.International journal of dermatology · 2024Observational
- Impact of vaccination with third generation modified vaccinia Ankara and sexual behaviour on mpox incidence in men who have sex with men: analysis among participants of the ANRS-174 DOXYVAC trial.The Lancet regional health. Europe · 2024Article
- Development and validation of the mpox stigma scale (MSS) and mpox knowledge scale (MKS).BMC public health · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As of October 28, 2022, a total of 28,244* monkeypox (mpox) cases have been reported in the United States during an outbreak that has disproportionately affected gay, bisexual, and other men who have sex with men (MSM) (1). JYNNEOS vaccine (Modified Vaccinia Ankara vaccine, Bavarian Nordic), administered subcutaneously as a 2-dose (0.5 mL per dose) series (with doses administered 4 weeks apart), was approved by the Food and Drug Administration (FDA) in 2019 to prevent smallpox and mpox disease (2); an FDA Emergency Use Authorization issued on August 9, 2022, authorized intradermal administration of 0.1 mL per dose, increasing the number of persons who could be vaccinated with the available vaccine supply
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.